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Background: Patients with reduced responsiveness to clopidogrel often have diminished platelet inhibition, a
factor associated with increased rates of major adverse cardiovascular events. Clinical trials that have focused on
reducing high on-treatment platelet reactivity (HPR) with an additional loading dose of clopidogrel have reported
varying effects. Prasugrel, a newer thienopyridine, exhibits a more consistent antiplatelet effect and more rapid
onset time when compared to clopidogrel. We hypothesize that prasugrel reloading would be more effective than
clopidogrel reloading in patients with HPR after an initial loading dose of clopidogrel.
Method/Design: Comparison of Prasugrel and Clopidogrel Reloading on High Platelet Reactivity in Clopidogrel-
loaded Patients Undergoing Percutaneous Coronary Intervention (PRAISE-HPR) is a prospective, randomized, open-
label, active controlled study. A total of 76 patients undergoing percutaneous coronary intervention (PCI), with HPR
after administration of a loading dose of clopidogrel will be randomly assigned to either prasugrel or clopidogrel
groups, and patients in each group will be reloaded with 20 mg of prasugrel or 300 mg of clopidogrel. The primary
endpoint will be HPR at 24 hours after PCI, as determined by the VerifyNow assay during the study period. The rate
of sustained high platelet reactivity and 30-day clinical outcomes will also be measured.
Discussion: PRAISE-HPR is a randomized controlled clinical trial to investigate the efficacy and safety of reloading
prasugrel and clopidogrel in suppressing residual high platelet reactivity. The results will be made publicly available
in the year 2013.
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Eligible Patients 
1. UA, NSTEMI 
2. Planned to PCI 
Clopidogrel 300 mg or 600 mg 
Randomization 
Conventional Treatment 
Residual PR < 240 
≥ 240 
LD of Prasugrel 20mg 
Prasugrel 5 mg/day 
LD of Clopidogrel 300 mg 
Clopidogrel 75 mg/day 
Primary Outcome: HPR at 24 hours 
Secondary Outcomes: in 30 days 
Cardiovascular death                              MI 
Stent thrombosis                               Stroke 
Target vessel revascularization              Bleeding 
Figure 1 Overall study design. ACS, acute coronary syndrome; UA,
unstable angina; NSTEMI, myocardial infarction without ST-segment
elevation; PCI, percutaneous coronary intervention; PR, platelet
reactivity; MI, myocardial infarction.
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In patients with acute coronary syndrome (ACS) who
undergo percutaneous coronary interventions (PCI), com-
mon recommendations for antithrombotic regimens in-
clude dual antiplatelet therapy with aspirin and clopidogrel
[1,2]. Clopidogrel is a thienopyridine derivative metabolized
by cytochrome P450 to an active metabolite that irrevers-
ibly inhibits platelet P2Y12 receptors [3]. Although the effi-
cacy of clopidogrel has been well established, it exhibits
pharmacodynamic variability in diverse conditions which
can be due to the loss-of-function CYP2C19 allele, drug-
drug interactions or clinical factors [4]. High on-treatment
platelet reactivity (HPR) after clopidogrel administration is
associated with adverse cardiovascular events [5-11] and
the rate of HPR can be reduced with either a higher loading
dose (LD) or maintenance doses (MD) of clopidogrel, or a
potent alternative drug [2,12-14]. The use of double doses
of clopidogrel and the more potent thienopyridine pra-
sugrel to reduce HPR and subsequent cardiovascular events
have not been successful, partially due to the studies being
conducted with low event rates and low-risk patients
[15,16]. Another issue concerning prior study design has
been the delayed administration of drugs, administered
after PCI in both cases. Therefore, a platelet reactivity (PR)
guided trial with reloading of a more potent drug in the
early phase of ACS, especially before PCI, is warranted.
Prasugrel is also a thienopyridine derivative. However,
the metabolism of prasugrel is much more efficient than
that of clopidogrel, because it occurs via esterases and has
less dependency on cytochrome P450 enzymes [17]. As a
result, prasugrel treatment results in more rapid onset,
more consistent conversion from the inactive prodrug to
active metabolite, and higher blood concentrations of the
active metabolite [18]. A LD of prasugrel 60 mg results in
more rapid, potent and consistent inhibition of platelet
function than clopidogrel LDs of 300 mg or 600 mg [19].
We hypothesize that for patients with HPR after an
initial LD of clopidogrel, reloading with prasugrel in the
early phase of ACS will reduce PR more effectively than




The primary aim of this study is to compare PR if 20 mg
of prasugrel is reloaded, followed by MDs of 5 mg daily,
versus clopidogrel reloading with 300 mg followed by
MDs of 75mg per day, prior to PCI in ACS patients with
HPR after an initial LD of clopidogrel.
Study design
PRAISE-HPR is a prospective, randomized, open-label,
active controlled study with two parallel study groups. It
will be conducted at Dong-A University Hospital inBusan, Republic of Korea. Participants will be randomly
allocated into prasugrel or clopidogrel reloading groups.
Clinical endpoints will be measured at four weeks post-
procedure. Recruitment of participants began in Novem-
ber 2012. The overall study design is depicted in Figure 1.
Study approval was granted by the Institutional Review
Board (IRB) of Dong-A University Hospital, and con-
secutive, eligible patients will be required to provide
written informed consent.Randomization
Random treatment assignments will be generated using
Excel spreadsheet software (Microsoft Corporation,
Redmont, DC, USA). Eligible patients will be randomly
assigned, on a 1:1 ratio, to receive reloading with either
prasugrel or clopidogrel. Treatment randomization will
be performed by independent personnel not involved in
the study.Approval
This study will be conducted according to principles
outlined in the Declaration of Helsinki. All patients must
provide written informed consent, understanding that
participation is voluntary and can be withdrawn at any
time without any negative consequences concerning their
current or future medical treatment. This study protocol
has been approved by the IRB of Dong-A University
Hospital.
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Male and female patients, aged between 20 and 80 years
for which the decision to undergo PCI within 24 hours
has been made, due to ACS without ST-segment eleva-
tion are eligible for the study (Table 1).
Patients requiring urgent PCI for ACS will be excluded
from entry, as will those with recent or planned medical
treatment with glycoprotein IIb/IIIa inhibitors, body
weight < 50 kg, contraindication to the study drug, a his-
tory of transient ischemic attack, active internal or
bleeding diathesis, hemoglobin < 10 g/dl, platelet count
< 100,000/mm3, renal insufficiency with serum creatin-
ine level > 2.5 mg/dl or significant hepatic dysfunction.
Intervention and comparator descriptions
Before randomization, 300 mg of aspirin and 600 mg of
clopidogrel will be administered as LDs according to the
conventional guidelines for ACS [2]. For those who have
already been receiving clopidogrel for five days or more,
300 mg of clopidogrel will be administered as a LD. PR
will be evaluated before PCI and defined as the time be-
tween the arrival of the patient at the angiography room,
and the beginning of coronary angiography. Angiography
will not begin before confirmation of PRU. Patients who
exhibit HPR defined as a PRU value of 240 units or more
by VerifyNow (Accumetrics, San Diego, CA, USA) will be
randomized and followed by assignment to either the
clopidogrel reloading group (clopidogrel 300 mg) or the
prasugrel reloading group (prasugrel 20 mg). Angiography
in patients with HPR will begin after administration of
the study drug. PR will be checked serially using the
VerifyNow (Accumetrics, San Diego, CA, USA) assay at
four hours, 24 hours and 30 days after PCI. Patients will
be required to visit the outpatient clinic at Day 30 for
measurement of PR. For patients discharged before Day 8,
a secondary visit at Day 15 will be recommended.
In the clopidogrel reloading group, 300 mg clopidogrel
will be reloaded, followed by MDs of clopidogrel 75 mg/Table 1 Eligibility criteria
Inclusion criteria
Subjects 20 to 80 years old
Male or female gender
ACS without ST-segment elevation
Planned to undergo PCI
Patients who provided written informed consent
ACS, acute coronary syndrome; PCI, percutaneous coronary intervention.day for 30 days. In the prasugrel reloading group, 20 mg
of prasugrel will be reloaded, followed by prasugrel ad-
ministration of 5 mg/day for 30 days.
Measurement of outcomes
The primary endpoint of this study will be HPR at 24 hours
after PCI, as determined by the VerifyNow (Accumetrics,
San Diego, CA, USA) assay during the study period
(Table 2). The optimal cutoff value is defined as 240 units,
as observed by Marcucci et al. [9]. Secondary endpoints
include major adverse cardiovascular events at 30 days after
PCI, including death from cardiovascular cause, myocardial
infarction (MI), stent thrombosis, hemorrhagic or non-
hemorrhagic stroke, and bleeding events defined by
Thrombolysis in Myocardial Infarction (TIMI), as well as
Bleeding Academic Research Consortium (BARC) criteria.
HPR at four hours or 30 days after PCI will also be
evaluated.
Adverse effects
Patients will be interviewed daily during admission and
at each visit after discharge regarding the occurrence of
any adverse events, including time of onset, duration
and severity. At each interview, patients will be assessed
for reported bleeding classified by the TIMI bleeding
classification scheme [20] as well as the BARC definition
[21]. All information regarding adverse events will be to
be presented on a case report form. The causal relation
to the study drug and the intensity of adverse events will
be evaluated by the investigators. Serious adverse events
will be reported to the IRB and study sponsor by the
principal investigator within 24 hours of being reported
by the subjects or the treating physicians.
Withdrawals
Participants are free to withdraw from trial participation
at their own request at any time without giving reasons
for their decisions. Additionally, the primary investigatorExclusion criteria
Body weight < 50 kg
Contraindications for study drugs
Urgent PCI for ACS
Use of glycoprotein IIb/IIIa inhibitor
History of transient ischemic attack
Active internal bleeding or bleeding diathesis
Upper gastrointestinal bleeding in the past six months
Hemoglobin < 10 g/dl or platelets < 100,000/mm3
Renal dysfunction (serum creatinine > 2.5 mg/dl)
Hepatic dysfunction (serum transaminase > three times normal limit)
Table 2 Primary and secondary outcomes
Primary outcome Secondary outcomes
HPR (PR ≥ 240 units) Death from cardiovascular cause
Myocardial infarction
Stent thrombosis
Hemorrhagic or non-hemorrhagic stroke
Target vessel revascularization
Bleeding event defined by Thrombolysis in Myocardial Infarction (TIMI) criteria and BARC
HPR, high platelet reactivity: more than 240 units determined via VerifyNow (Accumetrics, San Diego, CA, USA); PR, platelet reactivity; BARC, bleeding academic
research consortium.
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trial is deemed to be detrimental to the patient’s well-
being. Withdrawals will be documented in the case report
form and in the patient’s medical records with active
follow-up for ongoing severe adverse events. Distinction
will be made between patients who ‘withdraw from the
study’ versus ‘withdraw from the treatment’ in order to
preserve the ability to analyze endpoints for all parti-
cipants who underwent randomization, allowing for the
later possibility of intention-to-treat inferences.
Sample size
The sample size calculation is based on the primary out-
come and the primary analysis for the intention-to-treat
population. The sample size is calculated using the study’s
primary objective to detect a 15% difference in PR suppres-
sion between reloading with prasugrel and clopidogrel, to a
power of 80% to demonstrate difference. On the basis of
previous reports we assume the inhibition of PR after a LD
of clopidogrel to be approximately 55% of baseline [22].
The assumed inhibition of PR after LD of prasugrel is 70%.
This was calculated from studies showing a 30% higher
concentration of the active metabolite in patients of East
Asian ethnicity [23] and an approximate 90% inhibition of
baseline PRU two hours after a prasugrel 30 mg LD was
given in healthy Korean people [24]. We expect the differ-
ence in PR inhibition will be at least 15% when considering
ACS patients. We adjusted the sample size for an es-
timated follow-up loss rate of 20%, a two-sided level of sig-
nificance of α = 5%, which determined that 38 patients in
each group would be required to detect this difference with
a two-sided Student’s t test. A total of 76 patients will
be randomized and included in the analysis. We predict
that 50% of patients will exhibit HPR as determined by
VerifyNow (Accumetrics, San Diego, CA, USA) after re-
ceiving the clopidogrel LD. A total of 152 patients will be
screened and 76 patients will be randomized and included
in the analysis, with 38 patients in each group.
Statistical analysis
The focus of this trial is to compare the efficacy and safety
between both study groups. The statistical analyses will beperformed on the full analysis set, which will include data
from all randomized patients receiving at least one dose of
study medication. The safety analysis will include calcula-
tion of frequencies, rates of complications, and occurrence
of any serious adverse events reported in the two groups.
Descriptive statistics will be calculated according to
the scale level of the variables. Continuous data will be
analyzed using Student’s t test. The chi-square test will
be used for categorical variables. A value of P < 0.05 will
be used to denote statistical significance.
The effect of treatment will be expressed as relative risk
estimates and absolute risk reduction. The primary out-
come will be analyzed using multivariate logistic regres-
sion, adjusting for clinically relevant baseline imbalances.
The remaining secondary outcomes will be analyzed using
simple 2 × 2 tables and logistic regression. In all analyses,
statistical uncertainty will be quantified via 95% confi-
dence intervals. All statistical data will be analyzed using
SPSS Version 12.0 (SPCC Inc., Chicago, IL, USA).
Discussion
Although clopidogrel is an effective antiplatelet agent,
variability in patient response and potential high PR
remains a major shortfall. To date, recent studies focusing
on tailored antiplatelet therapy have not shown benefits.
However, a study comparing the efficacy of prasugrel and
clopidogrel in early reloading for the management of HPR
after clopidogrel LD has not been conducted. In addition,
guidelines for managing HPR before or during PCI in
ACS patients have not documented.
Our current investigation into reloading prasugrel ver-
sus clopidogrel for reductions of HPR in ACS patients
undergoing PCI is based on the hypothesis that prasugrel
reloading is superior to clopidogrel for HPR and adverse
event reduction, including periprocedural MI. Our proto-
col design has some safeguards to avoid performance and
evaluation bias. Randomization will be performed with
computer software. Data will be recorded and analyzed by
specialists who are not aware of treatment allocation.
A major safety concern for this trial is an increased risk
of bleeding. In TRITON-TIMI 38, higher rates of bleeding
(particularly non-coronary artery bypass graft-related
Lee et al. Trials 2013, 14:62 Page 5 of 6
http://www.trialsjournal.com/content/14/1/62TIMI major bleeding) were observed in the prasugrel
group [25]. However, in comparison to clopidogrel,
prasugrel provided greater protection from ischemic events
(particularly stent thrombosis, urgent revascularization and
MI). We therefore anticipate that the benefit of antiplatelet
efficacy will outweigh the increased risk of bleeding.
Regarding the issue of loading and maintenance
doses, previous reports have revealed that patients of
East Asian ethnicity exhibit on average 30% higher
levels of active metabolite compared to Caucasians,
with the implication that exposure of mean doses of
prasugrel to Asian subjects may not be appropriate
[23]. Other studies focused on Chinese subjects have
determined that 30 mg of prasugrel produces higher
concentrations of active metabolite and greater platelet
inhibition than 300 mg of clopidogrel [26]. Peak levels
of prasugrel active metabolites were found to be 67%
higher in Chinese subjects (calculated to be 39%
higher after adjustment for differences in body weight)
than in Caucasian volunteers. Taking into account eth-
nic differences in body weight and body mass index,
subjects of North-East Asian ethnicity appear to re-
ceive comparable effects with lower prasugrel LDs and
MDs. In an additional study conducted by our team,
healthy Korean volunteers administered with a 30 mg
LD of prasugrel exhibited significantly greater and
more rapid inhibition of PR than those administered
with a clopidogrel LD of 600 mg [24]. Yokoi et al.
compared several different prasugrel LDs and MDs in
Japanese patients and reported similar effects for a 10 mg
LD/ 2.5mg MD prasugrel regimen to a 300mg LD/75 mg
MD clopidogrel regimen [27]. These dosages are one sixth
and one fourth, respectively, of the current LD and MD
recommended by the manufacturer. We plan to conduct
the present study with lower LDs and MDs of prasugrel
than doses previously recommended.
Due to its rapid onset of action, the use of prasugrel can
be particularly favorable in patients requiring PCI at the
time of angiography who have not received thienopyridine
loading. LDs of prasugrel can be expected to provide more
potent platelet inhibition within a short period of time for
PCI support. The use of prasugrel therefore appears par-
ticularly suitable for patients undergoing PCI within hours
of the decision to use a thienopyridine. Furthermore, this
rapid onset agent can be administered immediately prior
to, or during PCI. This is particularly relevant for patients
with HPR remaining after a LD of clopidogrel.
The GRAVITAS [16] and TRIGGER-PCI [15] trials
aimed to detect reductions in HPR and concluded nega-
tive results. However, these studies did not use reloading
or include high risk, acute phase patients. Our study is
therefore the first to involve early manipulation of HPR
using a more potent agent before or during PCI. The
TRITON-TIMI 38 trial was noted for a lack of clopidogrelloading before randomization. Our trial design addresses
some ethical issues arising from such protocols, due to
closer similarities with real-world treatment. We anticipate
that our study will reveal the possible role of prasugrel
reloading and maintenance in improving clinical outcomes,
emphasizing its potential to become an integral compo-
nent in the management of patients undergoing PCI with
remaining HPR after a loading dose of clopidogrel.
Trial status
PRAISE-HPR began randomizing patients in November
2012. The principle investigator can be contacted by Email.
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